Table 1 Baseline characteristics.
Parameters | T3N1 (n = 2013) | T3N2 (n = 1103) | T3N3 (n = 799) | P Value |
|---|---|---|---|---|
Age at diagnosis, n (%) | Â | Â | Â | 0.003 |
 < 40 | 48 (2.38) | 30 (2.72) | 33 (4.13) |  |
 40–60 | 513 (25.48) | 318 (28.83) | 241 (30.16) |  |
 ≥ 60 | 1452 (72.13) | 755 (68.45) | 525 (65.71) |  |
Sex, n (%) | Â | Â | Â | 0.066 |
 Female | 534 (26.53) | 293 (26.56) | 245 (30.66) |  |
 Male | 1479 (73.47) | 810 (73.44) | 554 (69.34) |  |
Race, n (%) |  |  |  |  < 0.001 |
 White | 1576 (78.29) | 804 (72.89) | 530 (66.33) |  |
 Black | 193 (9.59) | 136 (12.33) | 98 (12.27) |  |
 Others | 244 (12.12) | 163 (14.78) | 171 (21.40) |  |
Marital Status, n (%) | Â | Â | Â | 0.068 |
 Unmarried, single | 292 (14.51) | 168 (15.23) | 109 (13.64) |  |
 Married | 1247 (61.95) | 708 (64.19) | 513 (64.21) |  |
 Previously married | 404 (20.07) | 176 (15.96) | 140 (17.52) |  |
 Unknown | 70 (3.48) | 51 (4.62) | 37 (4.63) |  |
Tumor location, n (%) |  |  |  |  < 0.001 |
 Body | 98 (4.87) | 84 (7.62) | 71 (8.89) |  |
 Cardia | 1199 (59.56) | 495 (44.88) | 242 (30.29) |  |
 Fundus | 54 (2.68) | 37 (3.35) | 26 (3.25) |  |
 Gastric antrum | 266 (13.21) | 189 (17.14) | 175 (21.90) |  |
 Greater | 50 (2.48) | 32 (2.90) | 31 (3.88) |  |
 Lesser | 134 (6.66) | 112 (10.15) | 91 (11.39) |  |
 Pylorus | 39 (1.94) | 32 (2.90) | 31 (3.88) |  |
 Others | 173 (8.59) | 122 (11.06) | 132 (16.52) |  |
Histology, n (%) |  |  |  |  < 0.001 |
 Signet ring cell adenocarcinoma | 267 (13.26) | 196 (17.77) | 172 (21.53) |  |
 Adenocarcinoma,intestinal type | 203 (10.08) | 142 (12.87) | 111 (13.89) |  |
 Adenocarcinoma, diffuse type | 76 (3.78) | 55 (4.99) | 75 (9.39) |  |
 Mucinous adenocarcinoma | 36 (1.79) | 24 (2.18) | 24 (3.00) |  |
 Adenocarcinoma, NOS | 1209 (60.06) | 592 (53.67) | 354 (44.31) |  |
 Others | 222 (11.03) | 94 (8.52) | 63 (7.88) |  |
Grade, n (%) |  |  |  |  < 0.001 |
 I | 75 (3.73) | 18 (1.63) | 15 (1.88) |  |
 II | 574 (28.51) | 266 (24.12) | 128 (16.02) |  |
 III | 1132 (56.23) | 714 (64.73) | 603 (75.47) |  |
 IV | 35 (1.74) | 27 (2.45) | 25 (3.13) |  |
 Unknown | 197 (9.79) | 78 (7.07) | 28 (3.50) |  |
Tumor size, n (%) |  |  |  |  < 0.001 |
 < 5 cm | 877 (43.57) | 470 (42.61) | 306 (38.30) |  |
 ≥ 5 cm | 678 (33.68) | 459 (41.61) | 433 (54.19) |  |
 Unknown | 458 (22.75) | 174 (15.78) | 60 (7.51) |  |
Therapy group, n (%) |  |  |  |  < 0.001 |
 OP only | 219 (10.88) | 185 (16.77) | 194 (24.28) |  |
 OP + adjuvant C/T ± RT | 286 (14.21) | 280 (25.39) | 352 (44.06) |  |
 CRRT + OP | 425 (21.11) | 176 (15.96) | 43 (5.38) |  |
 Neoadjuvant C/T + OP + adjuvant C/T ± RT | 171 (8.49) | 116 (10.52) | 73 (9.14) |  |
 C/T and others | 912 (45.31) | 346 (31.37) | 137 (17.15) |  |
Surgical therapy, n (%) |  |  |  |  < 0.001 |
 No surgery | 696 (34.58) | 209 (18.95) | 47 (5.88) |  |
 Partial gastrectomy | 858 (42.62) | 574 (52.04) | 454 (56.82) |  |
 Total (or near-total) gastrectomy | 459 (22.80) | 320 (29.01) | 298 (37.30) |  |
Radiation, n (%) |  |  |  |  < 0.001 |
 Yes | 1197 (59.46) | 579 (52.49) | 381 (47.68) |  |
 No/Unknown | 816 (40.54) | 524 (47.51) | 418 (52.32) |  |
Chemotherapy, n (%) |  |  |  |  < 0.001 |
 Yes | 1642 (81.57) | 875 (79.33) | 580 (72.59) |  |
 No/Unknown | 371 (18.43) | 228 (20.67) | 219 (27.41) |  |
Overall survival rate, % |  |  |  |  < 0.001 |
 1y | 73.1 | 73.3 | 65.8 |  |
 3y | 40.9 | 37.4 | 26.7 |  |
5y | 31.2 | 25.9 | 17.6 | Â |
